# Transgenic Mouse, ICSI & IVF Core

> **NIH NIH P30** · UNIVERSITY OF HAWAII AT MANOA · 2020 · $229,890

## Abstract

PROJECT SUMMARY/ABSTRACT – Transgenic Mouse, ICSI and IVF Core 
 The ability to introduce foreign genes or to selectively knock out endogenous genes in animals is of 
tremendous importance for basic and clinical research. In particular, with the advent of CRISPR/Cas 
technology, unprecedented opportunities for in vivo gene modulations have arisen. As such, transgenesis is a 
very powerful tool facilitating in vivo genome editing and transcription modulation, essential to dissect 
transcriptional, signaling, and environmental influences on the genetic basis of diseases but also for the 
development of novel therapeutic intervention strategies. Furthermore, mouse gamete manipulation, cloning 
technology, stem cell derivation, and -culture are a series of techniques that are essential for many successful 
research institutes in particular those with a focus on reproductive and developmental biology. 
 During Phase I, the University of Hawaii Transgenic Mouse, ICSI and IVF Core (TMII) at the Institute for 
Biogenesis Research was established and made significant progress towards the goal of becoming 
independently supported within fifteen years, accumulated a large array of equipment for micromanipulation of 
mouse gametes and embryo culture and recruited experienced researchers to staff the Core laboratory. 
Funding during Phase II strengthened and developed the COBRE Center into a state-of-the-art facility with an 
outstanding track record in providing efficient and economic access to transgenic animals and related 
technologies, including CRISPR technologies. The services were provided to COBRE faculty, University of 
Hawaii researchers and scientists around the country. The Core continued the development of novel gene 
delivery technology, including making significant progress on targeted gene insertion. 
 The objective of this Phase III COBRE application is to enhance and transform the Core into a self- 
sustained resource entity. Besides expanding our Core services, we will continue to work on improving the 
quality and delivery of these services and on enhancing and streamlining core operations. The Core will also 
enhance its outreach and focus on education and training as principal conduits for the acquisition of new 
customers at the University level. We will diversify our existing portfolio by coordinating and harmonizing our 
Core resources and services with those of the Molecular and Cellular Immunology (MCI) Core. We also aim to 
strengthen the core revenue base by increasing and diversify the contingent of investigators utilizing its many 
offerings. Specifically, we will expand our outreach, improve marketing activities and explore opportunities for 
collaborations with cores from other COBRE, INBRE and IDeA-CTR institutions.

## Key facts

- **NIH application ID:** 9994963
- **Project number:** 5P30GM131944-02
- **Recipient organization:** UNIVERSITY OF HAWAII AT MANOA
- **Principal Investigator:** STEFAN MOISYADI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $229,890
- **Award type:** 5
- **Project period:** 2019-08-13 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9994963

## Citation

> US National Institutes of Health, RePORTER application 9994963, Transgenic Mouse, ICSI & IVF Core (5P30GM131944-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9994963. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*